Nanobiotix (NASDAQ:NBTX – Get Free Report) and Ardelyx (NASDAQ:ARDX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Nanobiotix and Ardelyx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanobiotix | 1 | 1 | 4 | 0 | 2.50 |
| Ardelyx | 1 | 0 | 9 | 1 | 2.91 |
Valuation and Earnings
This table compares Nanobiotix and Ardelyx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanobiotix | $36.87 million | 51.88 | -$27.11 million | N/A | N/A |
| Ardelyx | $427.68 million | 3.00 | -$61.60 million | ($0.23) | -22.61 |
Nanobiotix has higher earnings, but lower revenue than Ardelyx.
Risk and Volatility
Nanobiotix has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Profitability
This table compares Nanobiotix and Ardelyx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanobiotix | N/A | N/A | N/A |
| Ardelyx | -13.58% | -38.11% | -11.85% |
Summary
Ardelyx beats Nanobiotix on 7 of the 13 factors compared between the two stocks.
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
About Ardelyx
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
